Co-targeting autophagy and MAPK pathways, by silencing ATG7 together with therapeutic agents against MEK, BRAF and CRAF (trametinib and RAF709), spared normal cells, while inducing apoptosis in KRAS mutated CRC and also PDAC cells [110]. This evidence concerns the gene KRAS and colorectal carcinoma.